David DeLucia
Known title: Chief Financial OfficerCIK: 0002040705
Associated companies
Transaction History
| KYNB | ▼ Sell | Tax Withholding | 22 | $188 | 9/6/2026 | View on chart |
| KYNB | ▼ Sell | Tax Withholding | 52 | $349 | 6/6/2026 | View on chart |
| KYNB | ▼ Sell | Tax Withholding | 60 | $410 | 3/6/2026 | View on chart |
| KYNB | ▼ Sell | Tax Withholding | 52 | $438 | 12/6/2025 | View on chart |
| KYNB | ▼ Sell | Tax Withholding | 53 | $641 | 9/6/2025 | View on chart |
| KYNB | ▼ Sell | Tax Withholding | 51 | $399 | 6/6/2025 | View on chart |
| KYNB | ▼ Sell | Tax Withholding | 2,325 | $907 | 3/6/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Kyntra Bio Names Andrew Singer to Board
Kyntra Bio has added Andrew E. Singer, MBA, to its board of directors. The move expands the company’s leadership team and could bring new expertise to its strategic planning. The appointment follows the company’s ongoing efforts to strengthen governance and support its growth initiatives. Investors may view the change as a sign of continued focus on development and operational improvement.
Kyntra Bio Names Andrew Singer to Board. Kyntra Bio has added Andrew E. Singer, MBA, to its board of directors. The move expands the company’s leadership team and could bring new expertise to its strategic planning. The appointment follows the company’s ongoing efforts to strengthen governance and support its growth initiatives. Investors may view the change as a sign of continued focus on development and operational improvement.